Ms. Anderson’s career spans over 30 years in regulated diagnostics and life science markets. She cofounded Veracyte in 2008 and served as the company’s President and Chief Executive Officer until 2016, when she was also appointed Chairman of the Board. She led Veracyte’s initial public offering in 2013 and has spearheaded commercialization of Veracyte’s market-leading products. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the boards of the Biotechnology Innovation Organization (BIO) and Castle Biosciences and on the steering committee for the Coalition for 21st Century Medicine. She is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson graduated from Indiana University of Pennsylvania with a Bachelor of Science degree in Medical Technology and in 2012 was honored with a “Distinguished Alumni” award. She has received numerous awards for her industry leadership, including: the Wallace H. Coulter Award for Healthcare Innovation (2017); “Fiercest Women in Life Sciences” (FiercePharma 2017); “100 Most Creative People in Business” (Fast Company, 2015); “Most Influential Women in Bay Area Business” and “Bay Area’s Most Admired CEOs” (San Francisco Business Times, 2013 and 2014); and “Women of Influence” (Silicon Valley Business Journal, 2013). Under Ms. Anderson’s leadership, Veracyte has been named a “Top Workplace” by the Bay Area News Group, based solely on employee feedback, for six consecutive years (2014-2019).